89bio to participate in goldman sachs 46th annual global healthcare conference

San francisco, june 04, 2025 (globe newswire) -- 89bio, inc. (the “company” or “89bio”) (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the company's management will participate in a fireside chat at the goldman sachs 46th annual global healthcare conference on wednesday, june 11, 2025 at 11:20 am edt and participate in one-on-one investor meetings.
ETNB Ratings Summary
ETNB Quant Ranking